TP53 and breast cancer: Interesting, however, was the fact that Cohen et al., 2018 had lower diagnostic performances (below 70%) in detecting colorectal, lung and breast cancers compared to other solid tumors combining cfDNA mutation analyses (including TP53) and proteomic information (CancerSeek) [97].